New cancer therapeutics: Target-specific in, cytotoxics out?

Drug Resistance Updates

Volumn 7, Issue 2, 2004, Pages 79-87

  Broxterman, Henk J ^a   Georgopapadakou, Nafsika H ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b METHYLGENE INC   (Canada)

Author keywords

(Phospho)proteomics; AEE788; Biomarkers; CI 1040; Erlotinib; Gefitinib; Gleevec; Imatinib; Iressa; PD0325901; Protein kinase inhibitors; SU 11248; SU 5416; Tarceva; Target selection; Trastuzumab; Xyotax; ZD1839; ZM447439

Indexed keywords

17 ALLYLAMINOGELDANAMYCIN; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CAPECITABINE; CYTOTOXIC AGENT; DOCETAXEL; ERLOTINIB; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GELDANAMYCIN; IMATINIB; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; N [4 [6 METHOXY 7 (3 MORPHOLINOPROPOXY) 4 QUINAZOLINYLAMINO]PHENYL]BENZAMIDE; OXALIPLATIN; PACLITAXEL; PACLITAXEL POLIGLUMEX; POLYGLUTAMIC ACID; PROTEIN TYROSINE KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; SEMAXANIB; SORAFENIB; SUNITINIB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; UREA DERIVATIVE; [4 [2 CYCLOPENTYL 9 (3 HYDROXYPHENETHYL)PURIN 6 YLAMINO]PHENYL]DIMETHYLPHOSPHINE OXIDE;

CANCER; CANCER RESEARCH; CANCER RESISTANCE; CANCER THERAPY; CLINICAL TRIAL; CONFERENCE PAPER; CYTOTOXICITY; DIARRHEA; DISEASE MARKER; DRUG DESIGN; DRUG MECHANISM; DRUG SPECIFICITY; DRUG TARGETING; FATIGUE; HUMAN; NAUSEA; NONHUMAN; PARESTHESIA; PRIORITY JOURNAL; PROTEOMICS; RASH; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN DISEASE; STOMATITIS; SUBCUTANEOUS FAT DISORDER; TUMOR CELL;

EID: 2942627403     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drup.2004.02.004     Document Type: Conference Paper

References (59)

1. Abrams, T.J., Lee, L.B., Murray, L.J., Pryer, N.K., Cherrington, J.M., 2003. SU11248 inhibits KIT and platelet-derived growth factor receptor β in preclinical models of human small cell lung cancer. Mol. Cancer Ther. 2, 471-478.
2. Alaoui-Jamali, M.A., Qiang, H., 2003. The interface between Erb and non-Erb receptors in tumor invasion: clinical implications and opportunities for target discovery. Drug Resist. Update 6, 95-107.
3. Azam, M., Daley, G.Q., 2003. B153 Molecular mechanism of Gleevec resistance revealed by the mutagenesis of BCR/ABL gene. Clin. Cancer Res. 9 (16 Suppl.), 6174S (abstract B153).
4. Azam, M., Latek, R.R., Daley, G.Q., 2003. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 112, 831-843.
5. Bashyam, S., Warner, S.L., Vankayalapati, H., et al., 2003. Characterization of a novel class of aurora-2 kinase inhibitors. Clin. Cancer Res. 9 (16 Suppl.), 6071S-6072S (abstract A12).
6. Beck, W.T., Grogan, T.M., Willman, C.L., et al., 1996. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res. 56, 3010-3020.
7. Bergers, G., Song, S., Meyer-Morse, N., Bergsland, E., Hanahan, D., 2003. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest. 111, 1287-1295.
8. Broxterman, H.J., Lankelma, J., Pinedo, H.M., 1996. How to probe clinical tumour samples for P-glycoprotein and multidrug-resistance-associated protein. Eur. J. Cancer 32A, 1024-1033.
9. Broxterman, H.J., Lankelma, J., Hoekman, K., 2003. Resistance to cytotoxic and anti-angiogenic agents: similarities and differences. Drug Resist. Update 6, 111-127.
10. Carbone, D.P., 2003. Epidermal growth factor receptor overexpression: the importance of context. J. Clin. Oncol. 21, 4268-4269.
11. Chen, J.-S., Lan, K., Hung, M.-C., 2003. Strategies to target HER2/neu overexpression for cancer therapy. Drug Resist. Update 6, 129-136.
12. Cheng, H.-C., Abdel-Ghany, M., Pauli, B., 2003. A novel consensus motif in fibronectin mediates dipeptidyl peptidase IV adhesion and metastasis. Clin. Cancer Res. 9 (16 Suppl.), 6182S-6183S (abstract B188).
13. Dalgarno, D.C., Bohacek, R., Stehle, T., et al., 2003. Structure-based design and X-ray crystallographic analysis of a potent and selective Src tyrosine kinase inhibitor for the treatment of cancer. Clin. Cancer Res. 9 (16 Suppl.), 6070S (abstract A5).
14. Ditchfield, C., Johnson, V.L., Taylor, S.S., et al., 2003a. ZM447439, a novel Aurora kinase inhibitor, prevents chromosome alignment and compromises spindle checkpoint function in human cells. Clin. Cancer Res. 9 (16 Suppl.), 6138S (abstract A279).
15. Ditchfield, C., Johnson, V.L., Tighe, A., et al., 2003b. Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. J. Cell Biol. 161, 267-280.
16. Fan, M., Chambers, T.C., 2001. Role of mitogen-activated kinases in the response of tumor cells to chemotherapy. Drug Resist. Update 4, 253-267.
17. Fojo, T., 2002. P53 as a therapeutic target: unresolved issues on the road to cancer therapy targeting mutant p53. Drug Resist. Update 5, 209-216.
18. Franks, M.E., Macpherson, G.R., Lepper, E.R., Figg, W.D., Sparreboom, A., 2003. New directions in cancer research 2003: technological advances in biology, drug resistance, and molecular pharmacology. Drug Resist. Update 6, 301-375.
19. Fukuoa, M., Yano, S., Giaccone, G., et al., 2003. A multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small lung cancer (The IDEAL 1 Trial). J. Clin. Oncol. 21, 2237-2246.
20. Gietema, J.A., de Vries, E.G.E., 2002. Clinical cancer research 2002: new agents and therapies. Drug Resist. Update 5, 192-203.
21. Goudar, R., Keir, S., Hjelmeland, M., et al., 2003. Combination therapy of inhibitors of the epidermal growth factor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Clin. Cancer Res. 9 (16 Suppl.), 6090S (abstract A88).
22. Hanahan, D., Weinberg, R.A., 2000. The hallmarks of cancer. Cell 100, 57-70.
23. Hanash, S., 2003. Disease proteomics. Nature 422, 226-232.
24. Hantschel, O., Nagar, B., Guettler, S., et al., 2003. A myristoyl/phosphotyrosine switch regulates c-Abl. Cell 112, 845-857.
25. Herrera, R., Sebolt-Leopold, J.S., 2002. Unraveling the complexities of the Raf/MAPkinase pathway for pharmacological intervention. Trends Mol. Med. 8, S27-S31.
26. Herbst, R., Bunn, Jr., P.A., 2003. Targeting the epidermal growth factor receptor in non-small cell lung cancer. Clin. Cancer Res. 9, 5813-5824.
27. Heinrich, M.C., 2003. Is KIT an important therapeutic target in small cell lung cancer? Clin. Cancer Res. 9, 5825-5828.
28. Hirsch, F., Varella-Garcia, M., Bunn, P.A., 2003. Epidermal growth factor receptor in non-small cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J. Clin. Oncol. 21, 3798-3807.
29. Huang, J., Soffer, S.Z., Kim, E.S., et al., 2004. Vascular remodeling marks tumors that recur during chronic suppression of angiogenesis. Mol. Cancer Res. 2, 36-42.
30. Johnson, B.E., Fischer, T., Fischer, B., et al., 2003. Phase II study of imatinib in patients with small cell lung cancer. Clin. Cancer Res. 9, 5880-5887.
31. Jones, R.J., Hanauske, A., Diaz-Rubio, E., et al., 2003. Final evaluation of Tarceva (Erlotinib) in combination with FOLFOX4 in patients with solid tumors. Clin. Cancer Res. 9 (16 Suppl.), 6095S (abstract A108).
32. Kajiyama, H., Kikkawa, F., Khin, E., Shibata, K., Ino, K., Mizutani, S., 2003. Dipeptidyl peptidase IV overexpression induces up-regulation of E-cadherin and tissue inhibitors of metalloproteinases, resulting in decreased invasive potential in ovarian carcinoma cells. Cancer Res. 63, 2278-2283.
33. Kamal, A., Thao, L., Sensintaffar, J., et al., 2003. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425, 407-410.
34. Kuenen, B.C., Rosen, L., Smit, E.F., et al., 2002. Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J. Clin. Oncol. 20, 1657-1667.
35. Liang, Y.Z., Gawad, C., Azorsa, D., et al., 2003. Targeting BRAF by siRNA in human melanoma. Clin. Cancer Res. 9 (16 Suppl.), 6096S (abstract A111).
36. Lynch, T., Ranson, M., Herbst, R., et al., 2003. Skin toxicity is not a clinically prognostic marker for tumor response to gefitinib (Iressa, ZD1839) in pre-treated patients with advanced non-small cell lung cancer. Clin. Cancer Res. 9 (16 Suppl.), 6086S (abstract A70).
37. Margulis, A., Fusenig, N., Hashimoto, K., Hanakawa, Y., Garlick, J.A., 2003. Abrogation of E-cadherin-mediated adhesion induces tumor cell invasion in human skin-like organotypic culture. J. Investig. Dermatol. 121, 1182-1190.
38. Menard, S., Gennari, R., Fagnoni, F., et al., 2003. Mechanism of action of pre-operative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin. Cancer Res. 9 (16 Suppl.), 6203S (abstract B270).
39. Mendelsohn, J., Baselga, J., 2003. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J. Clin. Oncol. 21, 2787-2799.
40. Morin, P.J., 2003. Drug resistance and the microenvironment: nature and nurture. Drug Resist. Update 6, 169-172.
41. Nagar, B., Hantschel, O., Young, M.A., et al., 2003. Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell 112, 859-871.
42. Neckers, L., Mimnaugh, E., Schulte, T.W., 1999. Hsp90 as an anticancer target. Drug Resist. Update 2, 165-172.
43. Nishizuka, S., Charboneau, L., Young, L., 2003. Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc. Natl. Acad. Sci. U.S.A. 100, 14229-14234.
44. O'Farrell, A.-M., Foran, J.M., Fiedler, W., 2003. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukaemia patients. Clin. Cancer Res. 9, 5465-5476.
45. Petricoin, E.F., Zoon, K.C., Kohn, E.C., Barrett, J.C., Liotta, L.A., 2003. Clinical proteomics: translating benchside promise into bedside reality. Nat. Rev. Drug Discov. 1, 683-695.
46. Ratain, M.J., Stadler, W., Smith, M., et al., 2003. Phase II study of BAY 43-9006 using the randomized discontinuation design in patients with advanced refractory cancer. Clin. Cancer Res. 9 (16 Suppl.), 6265S-6266S (abstract C254).
47. Safavy, A., McChesnet, J.D., Ainsworth, S.K., Helson, L., 2003. Receptor-based targeting strategy for bombesin receptor expressing cancers. Clin. Cancer Res. 9 (16 Suppl.), 6194S (abstract B236).
48. Schmidt, M., Lichtner, R.B., 2002. EGF receptor targeting in therapy-resistant human tumors. Drug Resist. Update 5, 11-18.
49. Schrohl, A.-S., Holten-Andersen, M., Sweep, F., Schmitt, M., Harbeck, N., Foekens, J., Brünner, N., 2003. Tumor markers. From laboratory to clinical utility. Mol. Cell. Proteomics 2, 378-387.
50. Shaffer, S.A., Baker Lee, C., Lai, M.S., et al., 2003. Cellular metabolism of Poly-L-glutamic acid-palitaxel (Xyotax) is mediated in part by lysosomal cathepsin B. Clin. Cancer Res. 9 (16 Suppl.), 6261S (abstract C237).
51. Sherman-Baust, C.A., Weeraratna, A.T., Rangel, L.B.A., et al., 2003. Remodeling of the extracellular matrix thruogh overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells. Cancer Cell 3, 377-386.
52. Solit, D.B., She, Y., Moasser, M., et al., 2003. Pulsatile administration of the EGFR receptor inhibitor gefitinib (Iressa, ZD1839) is significantly more effective than continuous dosing for sensitizing tumors to Taxol. Clin. Cancer Res. 9 (16 Suppl.), 6089S (abstract A83).
53. Tang, Y., Kesavan, P., Nakada, M.T., Yan, L., 2003. Tumor-stroma interaction: positive feedback regulation of EMMPRIN expression and MMP-dependent generation of soluble EMMPRIN. Clin. Cancer Res. 9 (16 Suppl.), 6184S (abstract B194).
54. Traxler, P., Allegrini, P.R., Brandt, R., 2003. Preclinical activity of AEE788, a potent new inhibitor of the ErbB and VEGF receptor kinases. In vivo profile of AEE788. Clin. Cancer Res. 9 (16 Suppl.), 6090S (abstract A87).
55. Vasilevskaya, I., O'Dwyer, P.J., 2003. Role of Jun and Jun kinase in resistance of cancer cells to therapy. Drug Resist. Update 6, 147-156.
56. Weisberg, E., Griffin, J.D., 2003. Resistance to imatinib (Glivec): update on clinical mechanisms. Drug Resist. Update 6, 231-238.
57. West, K.A., Castillo, S.S., Dennis, P.A., 2002. Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist. Update 5, 234-258.
58. Wilhelm, S., Carter, C., Tang, L., et al., 2003. BAY 43-9006 exhibits broad spectrum anti-tumor activity and targets raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Clin. Cancer Res. 9 (16 Suppl.), 6088S (abstract A78).
59. Xu, W., Yuan, X., Jung, Y.J., 2003. The heat shock protein 90 inhibitor geldanamycin and the ErbB inhibitor ZD1839 promote rapid PP1 phosphatase-dependent inactivation of Akt in ErbB2 overexpressing breast cancer cells. Cancer Res. 63, 7777-7784.